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Abstract: Tuberculosis (TB) remains the single biggest infectious cause of death globally, claiming
almost two million lives and causing disease in over 10 million individuals annually. Matrix
metalloproteinases (MMPs) are a family of proteolytic enzymes with various physiological roles
implicated as key factors contributing to the spread of TB. They are involved in the breakdown of lung
extracellular matrix and the consequent release of Mycobacterium tuberculosis bacilli into the airways.
Evidence demonstrates that MMPs also play a role in central nervous system (CNS) tuberculosis, as
they contribute to the breakdown of the blood brain barrier and are associated with poor outcome in
adults with tuberculous meningitis (TBM). However, in pediatric TBM, data indicate that MMPs may
play a role in both pathology and recovery of the developing brain. MMPs also have a significant
role in HIV-TB-associated immune reconstitution inflammatory syndrome in the lungs and the brain,
and their modulation offers potential novel therapeutic avenues. This is a review of recent research on
MMPs in pulmonary and CNS TB in adults and children and in the context of co-infection with HIV.
We summarize different methods of MMP investigation and discuss the translational implications of
MMP inhibition to reduce immunopathology.
Keywords: tuberculosis; matrix metalloproteinases; tuberculous meningitis; HIV-TB-associated IRIS;
extracellular matrix breakdown; adult; pediatric; lung; central nervous system
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1. Introduction
Tuberculosis (TB) remains one of the top 10 causes of death globally, with 1.6 million deaths
attributed to TB in 2017 [1]. Although the overall incidence of the disease is decreasing, there were
over 10 million new cases of TB reported in 2017 [1], suggesting that more work needs to be done on
disease prevention and cure. Tuberculous meningitis (TBM) is the most severe form of this disease and
leaves many surviving adults and children with severe neurological impairment [2]. The inflammatory
processes occurring during TB infection in the lungs and the neuro-inflammatory response as a result
of dissemination to the brain play key roles in disease outcome. In pulmonary TB (pTB), matrix
metalloproteinases (MMPs) are considered important in cavitary lung disease and the subsequent
spread of Mycobacterium tuberculosis (Mtb) from the lung parenchyma into the airways from whence
they can be expectorated to perpetuate infection [3]. They also contribute to the breakdown of the
protective blood brain barrier (BBB) and brain tissue destruction consequent to TBM [3]. In this
review, we discuss the current status of MMP research in pulmonary and central nervous system (CNS)
TB, and their potential dual role in pathology as well as neurodevelopment and recovery. We also
summarize potential novel treatment strategies that may target MMPs.
MMPs
MMPs are a superfamily of zinc- and calcium-dependent proteolytic enzymes that is well
conserved across species with 25 vertebrate MMPs (24 of which are found in humans) characterized
to date [4]. Several MMPs, including MMP-1, -3, -7, and -8, are located within a single gene cluster,
highlighting their essential role in fundamental physiologic processes [4]. Their primary function in
humans is degradation of the extracellular matrix (ECM) [5], which not only contributes to health by
providing tissue homeostasis but also has a role in many pathologic conditions [4]. MMPs fall under
the general category of metalloproteinases (MPs) of the Metzincin family, which function both on cell
surfaces (as sheddases, which release growth factors, death receptors, and death-inducing ligands),
and within the ECM [6]. They are divided into five sub-families, namely collagenases (MMP-1, -8,
and -13), gelatinases (MMP-2 and MMP-9), stromelysins (MMP-3 and MMP-10), elastases (MMP-7 and
MMP-12) and membrane-type MMPs (MT-MMP-1 to -5) [7,8].
MMPs are synthesized and released as proenzymes, known as zymogens, that are subsequently
activated when the zinc-thiol interaction between the catalytic and the pro-peptide domain is disrupted
by cleavage of the pro-peptide domain [8–10]. Due to the destructive nature of excessive activity, MMPs
are controlled by gene expression (transcriptional and post-transcriptional regulation), proenzyme
activation, and innate inhibitors. They are inhibited by α2-macroglobulin in the plasma or tissue
inhibitors of metalloproteinase (TIMPs) in the tissue [4]. TIMPs are endogenous protein regulators and
show tissue-specific, constitutive, or inducible expression [11]. There are four members of the TIMP
family (TIMPs 1-4), which bind MMPs non-covalently to inhibit activity. TIMP-3 acts on both MMPs
and tumor necrosis factor (TNF)-α converting enzyme (TACE) [9,11]. However, despite preference for
specific MMPs, they are able to inhibit all MMPs, binding them in a 1:1 molar stoichiometry [11].
Physiologically, MMPs have an important role in development (blastocyst implantation,
embryonic development, nerve growth), reproduction (ovulation, endometrial cycling, cervical
dilatation), and maintenance of homoeostasis (wound-healing, bone remodeling, angiogenesis,
and nerve regeneration) [4]. However, in various pathologies, MMPs have demonstrated a role
in both immuno-protection and tissue destruction. They contribute to activation of immune mediators
and leukocyte migration to sites of inflammation and infection by modulating cytokine and chemokine
activity [12]. They are also implicated in numerous pathologies such as cancer invasion and metastasis,
hypertension, rheumatoid and osteo-arthritis, CNS diseases, and may cause direct tissue destruction
at excessive concentrations [10,12]. In the lung, a number of MMPs contribute to tissue homeostasis,
such as MMP-7, -16, -19, -21, -24, -25, and -28 [4]. For example, lung epithelial cells express
MMP-7 that is essential in normal wound repair and plays a part in the chemotactic recruitment
of neutrophils [13]. In the CNS, MMPs are normally undetectable or present at very low levels
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(except for MMP-2) [10,14]. They can play a beneficial role in the CNS through their involvement
with tissue repair after injury [9,14] and are also found to be elevated postnatally in rat and mouse
CNS, suggesting pivotal roles in neuroplasticity and CNS development [15,16] such as synaptogenesis,
synaptic plasticity, and long-term potentiation [17].
2. Methods of Investigation
Quantification of MMPs can be an analytical challenge for several reasons. In TBM, a number
of methods of MMP investigation have been used, including ELISA, zymography and reverse
zymography for serum, and cerebrospinal fluid (CSF) (Table 1). ELISAs for MMPs are, however,
often limited by the absence of differentiation between active and inactive or degraded forms of
MMP, and multiplexed assays are often complicated by cross-reactivity between analytes due to
the protein’s common domains [8]. Additionally, the method of blood collection can impact the
concentration of MMPs, with higher concentrations reported in serum compared to plasma (both
heparin and EDTA) [8] due to release from leukocytes and platelets during clot activation. For MMP-1,
-8, and -9, plasma is recommended [18]. Brain tissue or granuloma samples have been examined using
immunohistochemistry [19,20] and MMP gene expression using PCR [20,21]. Newer techniques such
as analysis of gene polymorphisms, near-infrared optical imaging, and HPLC (high performance liquid
chromatography) together with inductively-coupled plasma mass spectrometry (ICPMS) are evolving
and promising analytic techniques that could improve the ability to profile all MMPs [8]. In addition
to human data, in vitro cell and animal models have also offered valuable insights.
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Table 1. Summary of recent matrix metalloproteinase (MMP) studies in pulmonary tuberculosis (TB) and central nervous system (CNS) TB.
Reference CNS orpTB Subjects Samples
Method of
Investigation Analytes Key Findings
Pulmonary TB (pTB)
Elkington et al.
[22,23] pTB
Adults (n = 6 proven pTB
patients, 6 controls with
cancer diagnosis)
Lung tissue
from biopsy Immunohistochemistry
MMP-1
MMP-7
Study examined affected lung in Mtb vs unaffected lung in
cancer patients
• MMP-1 and MMP-7 present in macrophages and
Langhans giant cells in granuloma, and MMP-1 in
adjacent epithelial cells, in PTB cases only
Kuo et al. [24] pTB
Adults (n = 101 confirmed
pTB cases—38 with
endobronchial TB,
68 without). All HIV
negative
Blood Genotyping
MMP-1 DNA (G-1607
GG) sequence single
nucleotide
polymorphisms
MMP-1 1G genotype was associated with endobronchial TB
on bronchoscopy
• MMP-1 1G genotypes were associated with a 9.86-fold
increased risk of developing tracheobronchial stenosis, in
patients with endobronchial TB
Wang et al. [25] pTB
Adult (n = 98 pTB cases,
49 healthy controls). All
HIV negative
Blood Genotyping
MMP-1(G-1067GG)
single nucleotide
MMP-12(Asn357Ser),
MMP-9(C-1562T)
polymorphisms
MMP-1 (-1607G) polymorphism increased the risk of
moderate and advanced lung fibrosis at one year in pTB
cases—the odds increased by 3.80 and 6.02 fold, respectively
for one copy and this remained after adjustment for age, sex,
initial disease score on chest radiograph, sputum bacterial
load, smoking status and presence of diabetes
• MMP-9 and -12 polymorphisms were not associated with
increased risk of developing lung fibrosis
Ganachari et al.
[26] pTB
Adults (n = 894 pTB cases,
1039 PPD+ controls
collected from 2 sites). All
HIV negative
Blood
Genotyping
Immunohistochemistry
of lymph node samples
for MMP-1 and MCP-1
-2518A>G SNP in
MCP-1 (rs1024611)
-1607_1608insG variant
in MMP-1 (rs1799750),
and 42 genomic control
SNPs
• MMP-1 allele 2G associated with TB disease
• MMP-1 2G/2G genotype associated with increased
lymph node MMP-1 in active TB cases compared to
other genotypes
Elkington et al.
[27] pTB
Adults (n = 33 HIV
uninfected pTB cases, 32
respiratory symptomatic
controls
Induced
sputum and
BAL
Luminex
(concentrations
normalized to total
protein)
MMP-1
MMP-2
MMP-3
MMP-7
MMP-8
MMP-9
MMP-12
TIMP-1
TIMP-4
• MMP-1, -3: pTB > controls
• MMP-2, -8, -9, -12, TIMP-1 and-2: pTB ≈ controls
• MMP-13, TIMP-3 and -4 undetectable
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Table 1. Cont.
Reference CNS orpTB Subjects Samples
Method of
Investigation Analytes Key Findings
Walker et al.
[28] pTB
Adults (n = 23 pTB cases,
21 controls—mixed
healthy and respiratory
symptomatic). Mixed HIV
status
Induced
sputum
Luminex
(concentrations
normalized to total
protein)
MMP-1
MMP-2
MMP-3
MMP-7
MMP-8
MMP-9
MMP-12
MMP-13
• MMP-1, -2, -3, -8: pTB > controls irrespective of
HIV status
• MMP-7 and -9: pTB ≈ controls
• MMP-12 and -13 undetectable
• In advanced HIV (CD4 < 200), pTB patients had
relatively lower sputum MMP-1, -2, -8 and -9
• MMP-1 and -2 increased in pTB patients with cavities
versus no cavities, and correlated with chest x-ray
inflammation score
Ganachari et al.
[29] pTB
Adults (n = 224 pTB cases,
42 controls). HIV negative Blood Genotyping
-2518A>G SNP in
MCP-1 (rs1024611)
-1607_1608insG variant
in MMP-1 (rs1799750)
and 42 genomic control
SNPs
• Greater proportion of patients with severe disease
carried the two locus genoype -2518 MCP-1 GG and
-1607 MMP-1 2G/2G, which was also associated with
delayed sputum smear conversion and increased fibrosis
Seddon et al.
[30] pTB
Adults (n = 78). Mixed
HIV status
Induced
sputum
Plasma
Luminex
ELISA
MMP-1
MMP-2
MMP-3
MMP-7
MMP-8
MMP-9
MMP-10
Also PINP, PIIINP,
PIIICP, CTX-I, CTX-III,
EMMPRIN
• Plasma PIIINP correlated with radiographic
inflammation score and sputum MMP-1 in pTB
• Plasma MMP-8 and PIIINP predictive of pTB diagnosis,
AUC of 0.82 (95% confidence interval 0.742–0.922, p <
0.001) by ROC curve analysis
Ugarte-Gil et al.
[31] pTB
Adults (n = 68 HIV
negative pTB cases, 69
healthy controls)
Longitudinal study, follow
up at 2, 8 and 24 weeks
Induced
sputum
Luminex (adjusted for
total protein)
ELISA
MMP-1
MMP-2
MMP-3
MMP-7
MMP-8
MMP-9
TIMP-1
TIMP-2
• MMP-1, -2, -3, -8, and -9: pTB cases > controls
• TIMP-1 and -2: pTB cases > controls
• Sputum MMP concentrations decreased with TB
treatment but TIMP concentrations initially rose
• Elevated sputum MMP-2, -8, -9 and TIMP-2 at TB
diagnosis, and elevated sputum MMP-3, MMP-8 and
TIMP-1 at two weeks were associated with two-week
sputum culture positivity
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Table 1. Cont.
Reference CNS orpTB Subjects Samples
Method of
Investigation Analytes Key Findings
Kubler et al.
[32] pTB
Adults (n = 97 pTB cases,
14 latent TB and 20 healthy
controls without latent TB)
Plasma ELISA
MMP-1
MMP-3
MMP-7
MMP-8
MMP-9
TIMP-1
TIMP-2
TIMP-3
TIMP-4
• MMP-1/TIMP1-4 ratios: pTB > latent TB and
healthy controls
Singh et al. [33] pTB
Adults (n = 17 confirmed
pTB cases, 18 respiratory
symptomatic controls. All
HIV uninfected)
BAL Fluid Not specified
MMP-1
MMP-2
MMP-3
MMP-7
MMP-8
MMP-9
MMP-12
MMP-13
• median MMP-1, -2, -3, -7, -8, and -9: pTB cases > controls
Chen et al. [34] PleuralTB
Adults (n = 18 TB pleuritis
cases, 18 controls with
congestive heart failure
and pleural effusion)
Pleural fluid ELISA
MMP-1
MMP-7
MMP-9
Also TNF-α
• Elevated TNF-α, MMP-1 and -9, which correlated with
the size of the effusion in cases
• MMP-7: cases ≈ controls
• TNF-α and MMP-1 positively correlated with degree of
pleural fibrosis at 6 months in cases
Sathyamoorthy
et al. * [35] pTB
Adults (n = 151 pTB cases,
109 symptomatic controls
and 120 healthy controls)
Plasma Luminex
MMP-1
MMP-3
MMP-7
MMP-8
MMP-9
MMP-10
MMP-12
MMP-13
• Plasma MMP-8: pTB cases > respiratory symptomatic
and healthy controls
• MMP-1: pTB cases > healthy controls only
• Gender specific differences in MMPs: MMP-8 in men
> women
Lee et al. [36] pTB
Adults (n = 167, HIV
negative,
culture-confirmed, drug
sensitive pTB)
Blood Luminex
MMP-1
MMP-3
MMP-8
MMP-9
MMP-12
Also cytokines and
cytotoxic mediators
• 26 cases were smear positive at 2 months (15.6%)
• RANTES concentration at diagnosis and MMP-8
concentration at 2 months predicted 2-month culture
status, AUC: 0.725 (0.624–0.827), and 0.632
(0.512–0.753) respectively
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Table 1. Cont.
Reference CNS orpTB Subjects Samples
Method of
Investigation Analytes Key Findings
Andrade et al. *
[37] pTB
Brazilian adults (n = 63
active PTB, 15 individuals
with LTBI, 10 healthy
controls)
Indian adults (n = 97
active PTB, 39 with LTBI,
40 uninfected healthy
controls)
North American adults (n
= 18 culture-confirmed TB,
11 non-tuberculous
mycobacteria infection
[NTM], 48 pulmonary
sarcoidosis)
All HIV negative
Plasma Luminex and ELISA
MMP-1
MMP-8
MMP-9
TIMP-1
TIMP-2
TIMP-3
TIMP-4
HO-1 and others
• MMP-1 (Brazilian cohort) and HO-1 (Indian cohort) were
elevated but inversely related (both cohorts) in PTB
patients compared to healthy controls (including those
with latent TB infection)
• MMP-1: pTB > sarcoid but pTB ≈ NTM (in
American cohort)
Ong et al. [38] pTB
Adults (n = 5 pTB cases)
Adults (n = 51 pTB cases,
57 healthy controls or a
subset of 11 patients in
each group for collagenase
experiments). All HIV
negative
Lung biopsies
Induced
sputum
Immunohistochemistry
Luminex
DQ collagen
degradation assay
H&E and
anti-neutrophil elastase
MMP-8
MMP-9 (adjusted for
total protein)
Also myeloperoxidase
(MPO) and neutrophil
gelatinase associated
lipocalin (NGAL)
• MMP-8 co-localized with neutrophils at the inner surface
of TB cavities
• Neutrophils were also immunoreactive for MMP-9
• Neutrophil activation markers MPO and NGAL: pTB
cases > controls and strongly correlated with
sputum MMP-8
• Sputum MMP-8: cavities > no cavities
• Induced sputum collagenase activity: pTB cases
> controls
• Collagenase activity correlates with MMP-8
concentration and is reduced by MMP-8 neutralization
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Table 1. Cont.
Reference CNS orpTB Subjects Samples
Method of
Investigation Analytes Key Findings
Sathyamoorthy
et al. [39] pTB
Adults (n = 15 pTB cases,
10 controls
Adults (n = 5 pTB cases, 5
controls)
Induced
sputum
Lung biopsy
RT-PCR
Immunohistochemistry
MT-MMP-1 (MMP-14)
• MT-MMP-1 RNA: pTB cases > controls
• Granuloma cell MT-MMP-1 immunoreactivity: pTB cases
> controls—only alveolar macrophages were positive
Brilha et al.
[40] pTB
Adult PTB vs control
(respiratory symptomatic
and healthy)
South African cohort;
Induced sputum, mixed
serostatus as described in
Walker et al. [28]
Indian cohort: BAL as
described in Singh et al.
[33]
Second South African
adult cohort: Induced
sputum for RNA (11 pTB
patients and 17 healthy
controls—all HIV
negative)
Induced
sputum and
BAL
Luminex for MMP
concentrations, RT-PCR
for RNA
MMP-10
• Induced sputum secreted MMP-10 and MMP-10 RNA:
pTB cases > controls
• BAL MMP-10: pTB cases > controls
Fox et al. [41] pTB
Peruvian cohort: Plasma
from adults (n = 50 pTB
patients 50 and matched
asymptomatic PPD
negative controls)
Indian cohort: BAL fluid
from adults (n = 15 pTB
patients and 15 matched
respiratory symptomatic
controls)
Plasma and
BAL Fluid Luminex
MMP-9 and
platelet-derived growth
factor (PDGF)-BB,
RANTES, P-selectin,
platelet factor-4 (PF4),
Pentraxin-3 (PTX3)
• Plasma MMP-9 correlated with platelet factors, PF4,
PDGF-BB and PTX3
• In BAL fluid, P-selectin concentrations correlated with
IL-1β, MMP-1, -3, -7, -8, and -9; PDGF-BB concentrations
correlated with MMP-1, -3, -8, and -9; RANTES
concentrations correlated with MMP-1, -8, and -9 as well
as IL-1β
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Table 1. Cont.
Reference CNS orpTB Subjects Samples
Method of
Investigation Analytes Key Findings
Singh et al. [42] pTB Adults (n = 5 pTB cases, 5non-TB controls Lung tissue Immunohistochemistry
MMP-3
IL-17
• IL-17 and MMP-3: pTB > control tissue
Tuberculous meningitis (TBM)
Matsuura et al.
[43] CNS
Adults (n = 21 meningitis
cases [7 TBM], 30 controls) CSF
Gelatin zymography
Immunohistochemistry
(demonstrated
immunoreactivity for
MMP-9 and -2 for
infiltrating
mononuclear cells)
MMP-9
MMP-2
TIMP-1
TIMP-2
• MMP-9, -2 and TIMP-1: cases > controls
• TIMP-2: cases ~ controls
• MMPs correlated positively with respective TIMPs
• No correlations between analytes and
proteins/cell counts
• MMP-9 and TIMP-1 concentrations positively associated
with neurological complications
Price et al. [44] CNS
Human monocytic
(THP-1) cells (in-vitro
study)
Adults (n = 23 TBM, 12
bacterial meningitis, 20
viral meningitis)
CSF
Northern Blot
Western Blot
Gelatin zymography
ELISA (for TIMP-1)
MMP-9
TIMP-1
(MMP-2)
In-vitro study:
• MMP-9 secretion increased in TB-infected cells at 24 h
(compared to controls)
• No difference in TIMP-1 secretion between TB-infected
cells and controls at 24 h (suggesting net proteolytic
activity). Moderate increase (5× compared to controls) at
48 h
• MMP-9 mRNA—undetectable in controls, detected at 24
h in TB-infected cells and increased at 48 h
• TIMP-1 mRNA—detected in controls. Only moderate
increase at 48 h in infected cells
Human data (Represented as activity on zymogram and as
MMP/CSF-leukocyte ratio):
• MMP-9 activity in TBM > other meningitides
• MMP/CSF leukocyte ratio in TBM > other meningitides
• MMP-9/CSF leukocyte ratio positively associated with
neurological complications
• MMP-2 was constitutionally expressed in the CSF, not
affected by infection
• TIMP-1 was not significantly elevated compared to other
meningitides or controls
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Table 1. Cont.
Reference CNS orpTB Subjects Samples
Method of
Investigation Analytes Key Findings
Thwaites et al.
[45] CNS Adults (n = 21 TBM)
CSF
Serum ELISA
MMP-9
TIMP-1
Also several cytokines
Measured pre- and post-treatment analyte concentrations:
All patients received streptomycin (20 mg/kg
intramuscularly daily; maximum, 1 g) and an oral regimen of
5 mg/kg isoniazid, 10 mg/kg rifampicin, and 30 mg/ kg
pyrazinamide for 3 months, followed by 3 drugs (isoniazid,
rifampicin, and pyrazinamide) for 6 months
• Pre-treatment: MMP-9 = 146 ng/mL, TIMP-1 =
463 ng/mL
• Post-treatment: MMP-9 = 70 ng/mL (p < 0.05), TIMP-1 =
269 ng/mL (p > 0.05)
• MMP-9 was not associated with outcome
• post-treatment was not significantly different to
pre-treatment concentrations
Lee et al. [46] CNS
Adults (n = 24 TBM, 23
acute aseptic meningitis,
10 controls [4 pTB and 6
non-inflammatory
neurological disorders])
CSF ELISAGelatin zymography
MMP-9
MMP-2
Measured MMP concentrations early (<7 days after
treatment) and late (after 7 days of treatment—range
10–106 days)
• MMP-9: early = 74 ng/mL, late = 123 ng/mL
Both early and late TBM concentrations > aseptic meningitis
and controls (p < 0.001)
• MMP-2: early = 75 ng/mL, late = 120 ng/mL
Early TBM > controls (p < 0.01) and late TBM > aseptic
meningitis (p = 0.01) and controls (p < 0.001)
• Both MMP-9 and -2 appear to increase temporally (after
treatment), but not evaluated statistically
• MMP-9 and -2 significantly higher in patients with
delayed neurological complications (p < 0.001 and
p < 0.01 respectively)
• MMP-9 correlated with CSF protein and white cell count
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Table 1. Cont.
Reference CNS orpTB Subjects Samples
Method of
Investigation Analytes Key Findings
Green et al.
[47] CNS Adults (n = 37 TBM) CSF ELISA
MMP-1
MMP-2
MMP-3
MMP-7
MMP-8
MMP-9
MMP-10
TIMP-1
TIMP-2
TIMP-4
Study compared the effect of dexamethasone on analyte
concentrations relative to a placebo group. Concentrations
were measured pre-treatment, on day 5 (3–8), day 30, 60,
and 270
• Significant decrease in MMP-9 early in dexamethasone
treatment (day 5, p = 0.01)—suggested this as potential
mechanism in which steroids improve outcome in TBM
• No relationship found between early decrease in MMP-9
and outcome
• Did not find any relationship between pre-treatment
MMP or TIMP concentrations and outcome, except:
lower MMP-2 associated with hemiparesis (p = 0.02)
• MMP-9 correlated with CSF neutrophil count (R2 = 0.52,
p < 0.001)
Rai et al. [48] CNS Adults (n = 36 HIVnegative, 28 HIV positive) CSF ELISA
MMP-2
MMP-9
• TBM case MMP > Controls for HIV− and HIV+
• MMP-2 and -9 concentrations not associated with
patient outcome
• MMP-2 associated with visual impairment
MMP-2 (ng/mL)
• Control: 60.5 (47.1–69.5)
• HIV− TBM: 77.3 (38.8–221.9)
• HIV+ TBM: 83.2 (48.8–286.5)
• HIV− versus HIV+ p > 0.05
MMP-9 (pg/mL)
• Control: 466.8 (432.1–986)
• HIV− TBM: 4962.2 (200–5966)
• HIV+ TBM: 3476.2 (491–5999.4)
• HIV− versus HIV+ p > 0.05
Int. J. Mol. Sci. 2019, 20, 1350 12 of 35
Table 1. Cont.
Reference CNS orpTB Subjects Samples
Method of
Investigation Analytes Key Findings
Marais et al.
[49] CNS
Adults (n = 34
HIV-associated TBM)
Sampled longitudinally
and stratified into
TBM-IRIS vs
TBM-non-IRIS
CSF
serum
Luminex
ELISA
MMP-1
MMP-2
MMP-3
MMP-7
MMP-9
MMP-10
MMP-12
MMP-13
TIMP-1
TIMP-2
Plus a large number of
cytokines and
chemokines.
CSF was analyzed 3–5 time points in HIV-TBM (n = 34) at
TBM diagnosis, initiation of ART (day 14), 14 days after ART
initiation, at presentation of TBM-IRIS, and 14 days
thereafter. 40 mediators in CSF were compared to blood and
between patients who developed TBM-IRIS (n = 16) vs those
who did not (TBM-non-IRIS; n = 18)
• MMP-9 and TIMP-1 were elevated in CSF at TBM
diagnosis, while MMP-1, -3, -7, and -10 were significantly
higher in blood
• HIV-TBM patients who subsequently developed
TBM-IRIS showed significantly elevated MMP-1, MMP-7,
MMP-10, TIMP-1 and TIMP-2 in the baseline CSF,
compared to those who did not
Majeed et al.
[50] CNS
C6 glioma cells (in-vitro
study)
Adults (n = 91 TBM cases,
16 controls)
CSF
Serum
Zymography
Reverse zymography
MMP-9
TIMP-1
In-vitro study: Infected C6 glioma cells with Mtb, and treated
them with MMP9-inhibitor (SB-3CT) and dexamethasone
• MMP-9: infected cells > uninfected cells
• Both drugs decreased MMP-9 concentrations
Human data: measured MMP-9 and TIMP-1 levels at
presentation (grouped according to TBM staging)
• CSF and serum MMP-9:
# cases > controls for all 3 stages
# higher MMP-9 concentrations at more severe
TBM stages
• CSF TIMP-1 detectable in controls and stage I TBM only.
Serum TIMP undetectable
• MMP-9 (ng/mL) CSF concentrations: Controls: 0.62 ±
0.4, Stage I TBM: 9 ± 0.87, Stage II TBM: 12 ± 1.34, Stage
III TBM: 16.9 ± 2.7
• MMP-9 (ng/mL) serum concentrations: Controls: 5.67 ±
2.45, Stage I TBM: 830.66 ± 83.07, Stage II TBM: 1202.55
± 136.81, Stage III TBM: 1679 ± 277.4
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Table 1. Cont.
Reference CNS orpTB Subjects Samples
Method of
Investigation Analytes Key Findings
Marais et al.
[51] CNS
Adults (n = 34 as
described above in Marais
et al. [49])
RNA from
blood,
Proteins from
CSF and
plasma
Microarray analysis
(RNA)
ELISA (CSF and
plasma)
>47,000 probes
• Whole blood transcriptional signature confirmed
elevated MMP-8 and MMP-9, with MMP-9 elevated at
protein level in baseline CSF in TBM-IRIS patients
• MMP-9 transcript remained elevated despite anti-TB and
anti-inflammatory (prednisone) treatment in TBM-IRIS
patients, possibly leading to degradation of the
extracellular matrix as a mechanism of tissue damage in
the central nervous system that is systemically reflected
in the blood
Mailankody et
al. [52] CNS Adults (n = 40 TBM) CSF ELISA
MMP-9
TIMP-1
• MMP-9 positively correlated with GCS (r = 0.3, p = 0.04)
and CSF albumin levels (r = 0.354, p = 0.025)
• MMP-9 negatively correlated with CSF glucose (r = −0.4,
p = 0.007)
• MMP-9 did not correlate with Q-alb or CSF
neutrophil count
• Higher median MMP-9 in patients with good outcome
(254 ng/mL) compared to bad outcome (192 ng/mL), but
not significant
Li et al. [53] CNS
Children
(n = 40 TBM,
8 controls)
CSF
(lumbar &
ventricular)
Serum
Luminex
MMP-9
MMP-2
TIMP-1
TIMP-2
First study to measure MMP (and TIMP) concentrations in
children with TBM
• Persistently elevated gelatinase (and inhibitor)
concentrations in paediatric TBM
• MMP-9 levels decreased early in response to TB
treatment (including steroid usage), but increased later
during the treatment phase
• No correlation between admission gelatinase levels and
Q-alb, clinical characteristics or poor outcomes
• Better outcomes (risk ratio 2.1, 95% CI 1.23–3.53, p = 0.01)
at 6 months for patients whose MMP-9 levels increased
during sampling period
Data presented as mean ± standard deviation or median (range) depending on information available from the study. * Provide diagnostic accuracy analysis. Matrix metalloproteinase
(MMP), tissue inhibitor of matrix metalloproteinase (TIMP), Enzyme-linked immunosorbent assay (ELISA), broncho-alveolar lavage (BAL), interleukin (IL), cerebrospinal fluid (CSF).
Anti-retroviral therapy (ART). Area under the curve (AUC). Cross-linked C-telopeptide of type I (CTX-I) and type III (CTX-III) collagen. Extracellular matrix metalloproteinase inducer
(EMMPRIN). Procollagen I N-terminal propeptide (PINP). Procollagen III N-terminal propeptide (PIIINP). Procollagen III C-terminal propeptide (PIIICP). Platelet-derived growth
factor-BB (PDGF-BB). Platelet factor-4 (PF4). Pentraxin-3 (PTX3). Receiver operating characteristics (ROC). Tumour necrosis factor (TNF). Regulated upon Activation, Normal T cell
Expressed, and Secreted (RANTES). Membrane type (MT). Monocyte chemoattractant protein 1 (MCP-1). Haematoxylin and Eosin (H&E). Single nucleotide polymorphism (SNP).
Albumin quotient (Q-alb).
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3. MMPs in pTB
Destructive pulmonary pathology is the hallmark of human tuberculosis, and Mtb is relatively
unique amongst pathogens for its ability to drive progressive destructive pulmonary pathology,
including cavitation, in immunocompetent adults. Cavities are critical in Mtb pathogenesis, as they
drive transmission (the most highly infectious patients are those with cavities), are immune-privileged
sites with high bacterial burden, and are poorly penetrated by anti-mycobacterial drugs, leading to
higher risk of treatment failure and relapse [54]. MMPs have been implicated in the pathology of
pulmonary tissue damage and cavitation, as collectively, they can degrade all fibrillary components of
the ECM (Figure 1). Previous reviews of MMPs in TB and mechanisms of cavitation have presented
substantial evidence of MMP activity in pTB disease [3,55], summarized below:
1. Elevated MMP concentrations (including MMP-1, -2, -8, -9) are consistently reported in respiratory
fluids [sputum, broncho-alveolar lavage (BAL), and pleural fluid] from TB patients compared to
patients with respiratory symptoms and/or healthy controls. Increased MMPs are associated
with various markers of pTB disease severity, most significantly MMP-1 with sputum smear
status, radiographic disease extent, and cavitation number in human pTB [28].
2. Significantly increased MMP gene expression is found in human respiratory cells (alveolar
macrophages, bronchial epithelial cells, and fibroblasts) and macrophages in response to Mtb
infection and/or stimulation by conditioned media from Mtb-infected monocytes (CoMtb),
resulting in increased MMP secretion [19,22,56]. Specifically, intracellular signaling involving
p38 and extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase pathway
(MAPK) are important for MMP upregulation in macrophages in response to Mtb infection.
3. Genetic associations implicate MMPs in TB disease risk (2G/2G MMP-1 genotype), endobronchial
TB and tracheobronchial stenosis (1G MMP-1 allele), TB dissemination (MMP-9 1562C/C
genotype), and post-TB chronic lung fibrosis (MMP-1 G-1607GG polymorphism).
4. Whilst some animal models of tuberculosis have failed to fully replicate the spectrum of human
pTB disease, following Mtb infection in human MMP-1-expressing transgenic mice, pathology
was found to be more similar to pTB in humans with increased alveolar tissue damage and
collagen destruction compared to wild type mice [27].
As MMPs have different cellular sources and substrate specificity, it is unsurprising that specific
MMPs have been associated with different roles within the same disease. For example, MMP-1 has
been most strongly implicated in the development of pulmonary cavities, whereas MMP-9 has been
implicated in Mtb dissemination.
Here, we review in detail more recent (since 2013) studies of pTB that have further delineated
cellular sources of MMPs in TB, mechanisms by which MMP activity is regulated in TB, and the
importance of the cellular and extracellular environment. We also describe studies that have evaluated
MMPs and matrix degradation products as TB biomarkers (Table 1, Section A).
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Figure 1. MMPs contribute to extracellular matrix (ECM) destruction in pulmonary TB (pTB). Lung 
TB granulomas comprise mycobacterium tuberculosis (Mtb) infected macrophages (purple), dendritic 
cells (beige), T (blue) and B (green) lymphocytes, and neutrophils (orange). These cells secrete 
numerous MMPs including MMP-1, -3, -7, -9, and -10, which may act in a proteolytic cascade. 
Evidence demonstrates their association with lung ECM breakdown, necrosis, and pTB disease 
severity. MMP-1 drives degradation of fibrillary type I, III, and IV collagen and is the key pulmonary 
collagenase. Neutrophil derived MMP-8 also contributes to collagen degradation, and both MMP-1 
and -8 are involved in cavity formation, which facilitates the transmission of Mtb by releasing the 
bacilli into the airways. Hypoxia augments monocyte and neutrophil MMP secretion acting through 
the hypoxia inducible factor (HIF)-1α transcription factor, an important regulator of the host response 
to oxygen deprivation. Mtb also promotes MMP activity via cellular networks involving immune and 
stromal cells. For example, lung fibroblasts have demonstrated upregulated MMP gene expression in 
response to Mtb infection or in the presence of monocytes infected with Mtb and MMP-1 secretion in 
response to Mtb-induced TNF-α. 
3.1. Collagen Degradation is an Early Pathological Event Promoted by Cell-Matrix Adhesion in TB 
Fibrillar type I, III, and IV collagen are major structural components of the human lung. In order 
to develop cavities, these collagen fibers must be cleaved. MMP-1 (also known as interstitial 
collagenase, collagenase-1) has emerged as the key MMP causing collagen degradation in pTB. In a 
recent study, of all the MMPs evaluated, MMP-1 was the most significantly increased in induced 
sputum of TB patients compared to respiratory symptomatic patients and healthy controls, along 
with MMP-3, which activates MMP-1 [57]. Further, MMP-1 positively correlated with chest 
radiograph inflammation score in HIV-uninfected patients and with sputum acid fast bacilli score 
and cavity frequency in HIV-infected and uninfected patients [57]. Procollagen III N-terminal 
propeptide (PIIINP), a matrix degradation product released during Type III collagen turnover, was 
increased in sputum of TB patients compared to controls and correlated with sputum MMP-1 but not 
with other sputum MMPs or cytokines measured, suggesting that MMP-1 is the key collagenase 
degrading Type III collagen in the lung [30]. 
Kubler et al. [32] investigated cavitary formation in a novel rabbit model of pTB, demonstrating 
increased MMP -1, -3, -7, -12, and -13 transcription in abnormal lung tissue. MMP-1, followed by 
MMP-3, was the most highly upregulated MMP with increased expression in the cavity walls 
compared to granulomatous tissue, and MMP-1 was found to be highly abundant in cavitary areas, 
supporting human data implicating MMP-1 in cavity formation. In contrast, TIMP-3 expression was 
lower in the cavitary compared to granulomatous areas of lung. 
Al Shammari et al. [58] examined lung biopsy specimens from pTB patients and demonstrated 
that collagen and elastin absence mapped to areas of caseous necrosis. In transgenic mice expressing 
human MMP-1 on the scavenger receptor A promoter/enhancer, infection with a pathological strain 
of Mtb (recently isolated from a patient) resulted in MMP-1 expression in the lung and development 
of granuloma with central areas of tissue destruction containing amorphous cellular debris, 
consistent with caseous necrosis. Wild-type or MMP-9-expressing mice infected with the same strain 
of Mtb did not develop this pathology despite a similar extent of pulmonary inflammation, 
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numerous MMPs including MMP-1, -3, -7, -9, and -10, which may act in a proteolytic cascade. Evidence
demonstrates their association with lung ECM breakdown, necrosis, and pTB disease severity. MMP-1
drives degradation of fibrillary type I, III, and IV collagen and is the key pulmonary collagenase.
Neutrophil derived MMP-8 also contributes to collagen degradation, and both MMP-1 and -8 are
involved in cavity formation, which facilitates the transmission of Mtb by releasing the bacilli into the
airways. Hypoxia augments monocyte and neutrophil MMP secretion acting through the hypoxia
inducible factor (HIF)-1α transcription factor, an important regulator of the host response to oxygen
deprivation. Mtb also promotes MMP activity via cellular networks involving immune and stromal
cells. For example, lung fibroblasts have demonstrated upregulated MMP gene expression in response
to Mtb infection or in the presence of monocytes infected with Mtb and MMP-1 secretion in response to
Mtb-induced TNF-α.
3.1. Collagen Degradation is an Early Pathological Event Promoted by Cell-Matrix Adhesion in TB
Fibrillar type I, III, and IV collagen are major structural components of the human lung. In order to
develop cavities, these collagen fibers must be cleaved. MMP-1 (also known as interstitial collagenase,
collagenase-1) has emerged as the key MMP causing collagen degradation in pTB. In a recent study,
of all the MMPs evaluated, MMP-1 was the most significantly increased in induced sputum of TB
patients compared to respiratory symptomatic patients and healthy controls, along with MMP-3,
which activates MMP-1 [57]. Further, MMP-1 positively correlated with chest radiograph inflammation
score in HIV-uninfected patients and with sputum acid fast bacilli score and cavity frequency in
HIV-infected and uninfected patients [57]. Procollagen III N-terminal propeptide (PIIINP), a matrix
degradation product released during Type III collagen turnover, was increased in sputum of TB
patients compared to controls and correlated with sputum MMP-1 but not with other sputum MMPs
or cytokines measured, suggesting that MMP-1 is the key collagenase degrading Type III collagen in
the lung [30].
Kubler et al. [32] investigated cavitary formation in a novel rabbit model of pTB, demonstrating
increased MMP -1, -3, -7, -12, and -13 transcription in abnormal lung tissue. MMP-1, followed by
MMP-3, was the most highly upregulated MMP with increased expression in the cavity walls compared
to granulomatous tissue, and MMP-1 was found to be highly abundant in cavitary areas, supporting
human data implicating MMP-1 in cavity formation. In contrast, TIMP-3 expression was lower in the
cavitary compared to granulomatous areas of lung.
Al Shammari et al. [58] examined lung biopsy specimens from pTB patients and demonstrated
that collagen and elastin absence mapped to areas of caseous necrosis. In transgenic mice expressing
human MMP-1 on the scavenger receptor A promoter/enhancer, infection with a pathological strain of
Mtb (recently isolated from a patient) resulted in MMP-1 expression in the lung and development of
granuloma with central areas of tissue destruction containing amorphous cellular debris, consistent
with caseous necrosis. Wild-type or MMP-9-expressing mice infected with the same strain of Mtb
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did not develop this pathology despite a similar extent of pulmonary inflammation, mycobacterial
burden, and cytokine profiles. The primary pathological difference was loss of collagen within the
MMP-1-expressing mouse granulomas. In a 3D extracellular matrix Mtb infection model, the addition
of collagen, but not gelatin, improved monocyte survival after Mtb infection, suggesting that loss of
collagen may promote cell death in TB. Together, this work supports the hypothesis that MMP-1 activity
leads to collagen degradation as a prelude to caseous necrosis in TB rather than as a consequence,
and that the integrity of the ECM may be an important determinant of the host immune response to
Mtb [58].
Following up on this, Brilha et al. [59] found that the ECM regulated MMP activity in TB. Culture
filtrate from Mtb-infected monocytes (CoMtb) increased monocyte adhesion to the extracellular matrix.
Adhesion to Type I collagen increased MMP-1 secretion from Mtb-infected monocytes by 60%, MMP-7
by 57%, and MMP-10 secretion by 90%. Similarly, adhesion to fibronectin (but not Type IV collagen)
increased MMP-1 secretion by 63% and MMP-10 secretion by 55%. Type I collagen adhesion increased
Mtb-driven TIMP-1, but TIMP-2 decreased. Monocyte migration, adhesion, and type I collagen
degradation were dependent on αVβ3-integrin activation, and integrin αVβ3 cell surface expression
increased in Mtb-infected monocytes following adhesion to type I collagen and fibronectin. This
suggests that Mtb infection promotes immune cellular interaction with the ECM propagating ECM
destruction. Whilst plasma concentrations of TIMP-1 are elevated in pTB in adults and children [60,61],
the concentration of antiproteases at the site of disease is evidently insufficient to prevent matrix
destruction, and TIMP-1 concentrations in pulmonary secretions are reduced in TB [27]. In cell culture
experiments, the increase in MMP secretion is not countered by an increase in TIMP-1 secretion [23],
consistent with Mtb skewing the protease-antiprotease balance towards matrix breakdown.
In addition to surface-bound collagenases, MT-MMPs may drive collagen degradation in TB.
MT-MMP-1 (also known as MMP-14) is expressed in TB granulomas [39]. Increased MT-MMP-1
transcript abundance was found in the sputum of pTB patients compared to controls. Mtb infection
increased monocyte cell surface MT-MMP-1 expression and resulted in collagen degradation, which
was largely MT-MMP-1-dependent. CoMtb similarly upregulated MT-MMP-1, which was p38 MAPK
dependent. MT-MMP-1 expression increased cell migration in a cellular model of TB infection, therefore
MT-MMP-1 may contribute to both collagenase activity and cell migration in TB [39].
3.2. Neutrophil-Derived MMP-8 Drives TB Immunopathology
Neutrophils are abundant in the lungs in pTB disease and can be both helpful and harmful in
TB [62–64]. Neutrophil-derived MMP-8 (neutrophil collagenase) has now emerged as the second main
collagenase contributing to TB immunopathology. A systematic investigation of the role of MMP-8 in
TB [38] demonstrated that neutrophils secrete MMP-8 in response to Mtb infection via NF-κβ and in
response to CoMtb, resulting in collagen degradation. Furthermore, elevated MMP-8 found in sputum
from pTB patients correlated well with neutrophil activation markers and TB severity score and
was associated with cavitation and involved with collagen breakdown compared to control sputum.
Neutrophils containing MMP-8 were found at the inner wall of pulmonary cavities in TB patients
and at the center of cavities in areas of caseous necrosis. Pro-catabolic AMP-activated protein kinase
(AMPK) phosphorylation was identified as a key regulator of neutrophil-derived MMP-8, but there
was no evidence of involvement of Akt/phosphoinositide-3-kinase (PI3K) pathway and mTOR/p70S6
kinase [38]. A further study found elevated sputum and plasma MMP-8 in patients with and without
HIV infection, and two studies have implicated MMP-8 in pulmonary immunopathology associated
with TB-associated immune reconstitution inflammatory syndrome (TB-IRIS—see below) [57,65].
In HIV-uninfected patients, elevated plasma MMP-8 was found in TB patients compared to respiratory
symptomatic patients and healthy controls and was found to differ by gender in TB patients, with
elevated MMP-8 in men compared to women [35]. Although men had a longer duration of cough
than women, the association with gender was independent of cough duration. Taken with the
MMP-1 data, these findings suggest that multiple collagenases contribute to lung matrix destruction
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in TB, potentially with macrophage-derived MMP-1 causing initial matrix breakdown and then
neutrophil-derived MMP-8 augmenting lung tissue damage once early cavitation occurs.
3.3. Hypoxia Drives Collagenase Activity in pTB
TB granulomas in several animal models have been shown to be hypoxic [66], but the interplay
with matrix turnover in human TB has only recently been investigated. The MMP-1 promoter
sequence has numerous putative hypoxia response elements, which are hypoxia-inducible factor
(HIF)-1-binding sites as well as NF-κB and activated protein-1 (AP-1)-binding sites [67]. HIF-1α
is a heterodimeric transcription factor, which is a key regulator of the host response to oxygen
deprivation. Positron emission tomography–computed tomography (PET-CT) study of human pTB
lesions with the hypoxia-specific tracer [18F] fluoromisonidazole ([18F]FMISO) has demonstrated
severe hypoxia in radiologically abnormal areas [67]. Experimental hypoxia or HIF-1α stabilization
using dimethyloxalyl glycine (DMOG) increased expression and secretion of MMP-1 in Mtb-infected
macrophages without affecting Mtb growth. A similar effect of experimental hypoxia on MMP-1
secretion in response to Mtb-stimulation (via CoMtb) on normal human bronchial epithelial cells was
observed. Mtb increases HIF-1α accumulation, even in normoxia, and HIF-1α is found in TB granuloma
co-localizing with epithelioid macrophages and multinucleate giant cells [67], demonstrating a complex
interplay between Mtb infection, hypoxia, and matrix breakdown, which together can be predicted to
cause lung cavitation.
Ong et al. [68] recently demonstrated that hypoxia (or HIF-1α stabilization) exacerbates
neutrophil-derived Mtb-driven MMP-8 secretion. The formation of neutrophil extracellular traps
(NETs) in response to direct infection of neutrophils by Mtb was decreased in the presence of
hypoxia, but neutrophil phagocytosis of Mtb was not affected. Furthermore, hypoxia increased
neutrophil survival following Mtb infection compared to normoxia and increased neutrophil-driven
matrix destruction, suggesting that hypoxia in pTB lesions may facilitate Mtb survival and promote
tissue destruction.
3.4. MMP and Cytokine Networks Enhance Tissue Damage in TB
Cellular networks lead to a tissue degrading phenotype in pTB, upregulating MMPs by a number
of pathways without a compensatory increase in TIMPs. Cell-cell networks involving respiratory
epithelial cells and fibroblasts in addition to immune cells result in synergistic MMP upregulation in
TB [3].
MMP-10 (stromelysin-2) was not formerly well studied in TB. However, as a key activator of
MMP-1, recent work demonstrated that MMP-10 drives collagenase activity in cell culture, and its
upregulation in macrophages was induced by virulent Mtb in an ESAT-6-dependent manner via
p38 and ERK MAPK [40]. Elevated MMP-10 was found in respiratory fluids (induced sputum and
BAL fluid) in TB patients compared to respiratory symptomatic controls, suggesting it may play an
important role in human disease operating within a proteolytic cascade.
A recent study by Fox et al. [41] identified a novel role for platelets in amplifying Mtb-driven
MMP-1, -3, -7, and MMP-10, and interleukin (IL)-1β secretion from monocytes without increasing
TIMP-1 and -2 levels. Similar to MMP-10, MMP-3 can activate MMP-1, and thus a predicted outcome
was increased collagenase activity. When Mtb was co-cultured with monocytes and platelets in
a fluorescence model using dye-quenched (DQ) collagen, significantly increased type 1 collagen
degradation was found compared to incubation with monocytes or platelets alone. Platelet-derived
mediators (P-selectin, RANTES, platelet-derived growth factor (PDGF)-BB) were present in BAL fluid
from TB patients at increased concentrations compared to BAL from non-TB respiratory symptomatic
patients and correlated with multiple MMPs (including MMP-1, -8, -9) and IL-1β.
IL-17 is expressed in human TB granulomas [42]. Supplementation with IL-17 enhanced
CoMtb-induced MMP-3 secretion from human distal small airway epithelial cells without
compensatory TIMP-1/2 upregulation. MMP-9 secretion was inhibited by IL-17 while MMP-1, -7,
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and -8 were unchanged. IL-17 enhanced CoMtb-driven MMP-3 upregulation in normal human
bronchial epithelial cells via p38 MAPK-dependent and the PI3K pathway. In fibroblasts, CoMtb-driven
MMP-3 secretion was augmented by both IL-17 and IL-22 [42].
In pleural TB, MMP-1, MMP-9, and TNF-α concentrations were elevated in pleural fluid compared
to pleural fluid from heart failure controls [34]. MMP-1 and -9 were secreted by pleural mesothelial cells
in response to Mtb-stimulation. TNF-α strongly correlated with MMP-1 secretion and was found to be
a potent stimulus of MMP-1 upregulation by pleural mesothelial cells in response to Mtb. In pericardial
TB, concentrations of MMP-1, MMP-2, and TIMP-1 were significantly elevated in pericardial fluid,
while MMP-7 and MMP-9 were higher in blood of patients with and without HIV-infection [69].
Differential abundance was also detected at mRNA level for MMP-2, MMP-9, TIMP-1, and TIMP-2.
In summary, Mtb promotes MMP activity and collagen degradation via cellular networks,
likely involving monocytes, macrophages, neutrophils, platelets, and epithelial cells in the
airways and mesothelial cells in the pleural space. In addition to previously described roles for
monocyte-derived Oncostatin M and TNF-α enhancing MMP-1 secretion from fibroblasts [70],
Mtb-driven (ESAT-6-dependent) MMP-10 and IL-17-augmented MMP-3 may propagate collagenase
activity in cellular networks via MMP-1 activation. An outstanding question is the relative contribution
of direct cellular infection versus intercellular networks in causing lung cavitation in vivo.
Furthermore, whilst macrophages and stromal cells are established sources of MMPs in TB,
the role of T cells in MMP-related pathology is unclear. T cells are critical to an efficacious host
immune response to Mtb, yet they also contribute to immune-mediated tissue damage. To exemplify,
a greater purified protein derivative (PPD) response associates with subsequent development of
pulmonary TB [71] and immune checkpoint inhibition for cancer associates with development of active
TB [72,73]. In contrast, in advanced HIV-induced immunocompromise, pulmonary cavitation rarely
occurs—despite high mycobacterial load within the lung—unless immune reconstitution takes place
with therapy. The knowledge gap defining what comprises a protective T cell response versus what
contributes to MMP-mediated tissue damage is a challenge to the development of rational strategies
that may limit pathology after treatment initiation or alternatively prevent cavitation to break the cycle
of transmission.
3.5. Intracellular Regulation of MMP Activity in pTB
Regulation of MMP-1 along with MMP-3 and MMP-9 by the PI3K pathway in TB has been
investigated in normal human bronchial epithelial cells stimulated by intercellular networks [74].
Inhibition of the PI3K p110α subunit led to increased MMP-1, whereas downstream inhibition of Akt,
mTOR, and p70S6 kinase led to reduced MMP-1. MMP-3 was inhibited by blockade at all three points
in the pathway, whereas MMP-9 was increased by blockade at PI3K p110α subunit, decreased by
blockade at Akt, and increased by blockade at mTOR or p70S6 kinase, indicating that regulation was
complex and possibly involved epigenetic mechanisms [74].
Subsequent work has demonstrated epigenetic control of Mtb-driven MMP-1 and -3 expression
by changes in histone acetylation in macrophages and normal human bronchial epithelial cells in a
cell-type specific manner [75]. Mtb also inhibits negative regulatory pathways in directly infected
human macrophages that function to limit MMP-1 secretion by inducing microRNAs that target PI3K,
mTOR-containing complex 1 (mTORC1), and MAPK-interacting kinase (MNK) pathways, which
together inhibit MMP-1 gene expression [76]. Therefore, Mtb not only increases collagenase activity by
inducing macrophage MMP-1 and -10 secretion via p38 and ERK MAPK, it also effectively switches
off inhibition of MMP-1 gene expression by interfering with PI3K and MNK pathway- regulation of
MMP-1 inhibition [76].
Andrade et al. [37] observed elevated plasma MMP-1 and heme oxygenase (HO)-1 in TB patients
compared to latently TB-infected asymptomatic controls. There was an inverse relationship between
plasma MMP-1 and HO-1, and active TB patients were found to be either plasma MMP-1-high, plasma
HO-1 low, or plasma MMP-1-low, HO-1-high. HO-1 is an antioxidant that catalyses the first step
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of the oxidative reaction that degrades the heme group contained in several proteins (including
haemoglobin and myoglobin) and is immunomodulatory [77]. In vitro, both MMP-1 and HO-1 were
induced in a dose-dependent fashion by Mtb. HO-1 was determined to be ESAT-6-dependent and
required replicating bacilli, whereas MMP-1 secretion did not. In murine macrophages, HO-1-induced
carbon monoxide (CO) production inhibited MMP-1 at the transcriptional level by inhibiting activation
of c-JUN/AP-1, suggesting that Mtb-driven HO-1 may serve to limit MMP-1 [37]. Together, these
findings demonstrate the complexity of MMP regulation with a balance between stimulatory and
inhibitory pathways.
3.6. MMPs as Biomarkers of TB Disease
MMPs have been evaluated as diagnostic biomarkers of active TB. The previously described
study by Sathyamoorthy et al. [35] reported that MMP-8 was the most discriminatory MMP for active
TB in plasma, reporting an area under the curve (AUC) of 0.77 (0.80 for men and 0.72 for women) in
comparison to non-TB respiratory symptomatic patients by receiver operating characteristics (ROC)
curve analysis.
Following the demonstration that plasma PIIINP correlated with radiographic inflammation score
and sputum MMP-1 in pTB, PIIINP was explored alongside other matrix degradation products as a
peripheral biomarker of pTB disease [30]. Plasma PIIINP was combined with procollagen III C-terminal
propeptide (PIIICP), MMP-2, MMP-7, MMP-8, and body mass index (BMI) in a TB prediction model
in comparison to a mixed group of non-TB respiratory symptomatics and healthy controls. The final
model, which included only those variables predictive after adjustment for all the others, included
only MMP-8 and PIIINP, giving an AUC of 0.82 (95% confidence interval CI 0.742–0.922, p < 0.001) by
ROC curve analysis.
In the aforementioned study by Andrade et al. [37], elevated plasma MMP-1 and HO-1 were
highly discriminatory for active TB compared to latent TB. However, the comparator group of
latent TB patients was asymptomatic. In an analysis including patients with other granulomatous
pulmonary conditions, MMP-1 was significantly elevated in active TB (n = 18) compared to patients
with sarcoidosis (n = 48) but not compared with patients with non-TB mycobacterial infection (n = 11).
TIMP-1 has been evaluated in active TB compared to patients with pneumonia. However, the sensitivity
was only 62.3% for a specificity of 45.95% [60]. It is possible that a panel of biomarkers that combine
elements of tissue remodeling (MMPs, TIMPs, and matrix degradation products) may be more helpful
than focus on a single component given the complexity of their interactions.
A limited number of studies to date have evaluated MMPs as biomarkers of treatment response
in pTB. Ugarte-Gil et al. examined sputum MMPs longitudinally in relation to culture conversion and
TBScore (which is associated with mortality risk) in a study of Peruvian patients [31]. Elevated sputum
MMP-2, -8, -9, and TIMP-2 at diagnosis (but not TBScore) and elevated sputum MMP-3, MMP-8,
and TIMP-1 at two weeks were associated with two-week sputum culture positivity. A study of
Taiwanese patients found a modest association between elevated plasma MMP-8 and sputum culture
positivity, both tested at two months [36]. An association between elevated serum MMP-1 and -8
over the first six weeks of treatment and delayed sputum culture conversion has been reported [78].
Further studies to evaluate MMPs and matrix degradation products as biomarkers of TB disease are
in progress.
3.7. MMPs in TB-IRIS
TB is the leading cause of death among HIV-1-infected persons, and the World Health
Organization (WHO) African region accounted for 72% of the global burden of HIV-associated
TB in 2017 [1]. There were 464,633 cases of HIV-TB notified in 2017 globally, and 84% were on
antiretroviral therapy (ART), which is an essential, life-saving intervention for HIV infection. However,
ART-mediated immune system recovery in the setting of Mtb infection may lead to a pro-inflammatory
state in the form of IRIS, presenting as TB-associated IRIS (TB-IRIS), which frequently complicates
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the otherwise beneficial dual therapy for HIV-1 and TB [79]. Two forms of TB-IRIS are recognized:
paradoxical, which occurs in patients established on antituberculosis therapy before ART, but who
develop acute, recurrent, or new TB symptoms and pathology after ART initiation; and unmasking
TB-IRIS in patients not receiving treatment for TB when ART is started but who present with active
TB within three months of starting ART [80]. The most common and most frequently studied form of
HIV-associated IRIS is the paradoxical TB-IRIS with incidence in adults ranging between (19–57%) and
lower incidence in children [81]. A recent randomized controlled trial demonstrated that prednisone
therapy during the first four weeks after the initiation of ART for HIV infection resulted in a lower
incidence of TB-IRIS than placebo without evidence of an increased risk of severe infections or
cancers [82]. The pathophysiology of paradoxical TB-IRIS remains incompletely defined. The majority
of studies evaluating MMPs have been conducted in adults, and this section of the review focuses on
studies related to adult TB-IRIS.
The hypothesis that dysregulated MMP activity may play a role in immunopathology and tissue
destruction in TB-IRIS patients was investigated for the first time by Tadokera et al. [83] through a
comprehensive analysis of MMP-1, -2, -3, -7, -8, -9, -10, -11, -12, and -13 as well as TIMP-1 and -2
gene expression in Mtb stimulated peripheral blood mononuclear cells (PBMC) from 22 patients who
developed paradoxical TB-IRIS compared to 22 similar HIV-TB co-infected, non-IRIS control patients.
Protein secretion in the form of MMP pro-enzyme content was also investigated using multiplex
assays in peripheral blood mononuclear cell (PBMC) culture supernatants and serum samples using
the Luminex platform and ELISA for TIMP-1 and -2. Transcript levels were increased in TB-IRIS
patients for MMP-3, -7, and -10, while protein secretion was higher for MMP-1, -7, -8, and -10 in
stimulated cultures compared to the control patients. Serum MMP-7 concentration was elevated in
TB-IRIS, and two weeks of clinically beneficial corticosteroid therapy [84] decreased this level, although
not significantly.
The association between the development of paradoxical TB-IRIS and increasing MMP-1, -2, -3, -8,
and -9 concentrations during ART was investigated in plasma from a cohort of 148 HIV-infected adults
with advanced HIV and TB before ART initiation and four weeks later [65]. This study found that
median concentrations of MMP-1, -2, and -3 decreased, while MMP-8 and -9 increased significantly
during ART, and a greater early MMP-8 increase was associated with both TB-IRIS development and
decreased long term lung function following TB cure. The results were broadly consistent with the
Tadokera study [83], although in that study, MMP-8 transcript abundance was not increased in IRIS in
Mtb-stimulated PBMC. This is possibly because MMP-8 is predominantly secreted by neutrophils and
present in pre-synthesized granules, thus these changes would not be identified by RNA analysis of
PBMC [38].
A large systematic study of HIV-associated TB that comprised of (i) a cross-sectional study
of HIV-1-infected and uninfected TB patients and controls, and (ii) a prospective cohort study of
HIV-1-infected TB patients at risk of TB-IRIS evaluated plasma and sputum MMP concentrations
using Luminex multiplex assays [57]. The results were analyzed in conjunction with plasma PIIINP
(determined by ELISA), a degradation product of collagen type III known to be released by matrix
destruction in pTB [30]. MMP activity differed between HIV-1-infected and -uninfected TB patients.
In HIV-uninfected TB patients, MMP activity was prominent in the pulmonary compartment and
MMP-1 was dominant, whereas HIV-1-infected TB patients had reduced pulmonary MMP-1, -2, and -9
concentrations and reduced cavitation but increased plasma PIIINP compared to HIV-1-uninfected
TB patients. TB-IRIS was associated with elevated extrapulmonary extracellular MMP concentrations
(measured in plasma) both before and during TB-IRIS onset. Plasma MMP-8 was the most significantly
increased and correlated with plasma PIIINP concentration as well as neutrophil count. This was
likely driven by Mtb antigen, as TB-IRIS patients with a positive urinary LAM (lipoarabinomannan)
result had higher plasma MMP-3, -7, and -8 concentrations compared to urine LAM negative TB-IRIS
patients. Consequently, the compartmentalization of MMP activity differs between immunocompetent
adults, where it is primarily within the lung, whereas in advanced HIV infection, MMP dysregulation
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is more systemic. In an in vitro culture model, Mtb-induced matrix degradation was suppressed by the
MMP inhibitor doxycycline, suggesting MMP inhibition as a possible novel host-directed therapeutic
strategy for preventing and/or treating TB-IRIS [57].
Overall, these studies indicate that TB-IRIS is associated with a distinct pattern of MMP gene and
protein activation. In addition to the beneficial effect of corticosteroid therapy [82], modulation of
dysregulated MMP activity may represent a novel therapeutic approach to alleviate TB-IRIS in HIV-TB
patients undergoing treatment.
4. MMPs in TBM
4.1. The Blood Brain Barrier (BBB)
The BBB is a highly-selective permeability barrier comprised of specialized capillary endothelial
cells with tight junctions, astrocytic foot processes, and pericytes [85]. It is integral in maintaining
homeostasis in the CNS by the stringent regulation of molecular access to prevent entry of
toxins and organisms into the brain. Increased permeability of the BBB is considered a hallmark
of neuroinflammation and CNS infection [85], and research has implicated MMPs in BBB
compromise [86,87]. Astrocytes, which form an integral component of the BBB, are known to
release MMPs in response to disease and may therefore contribute to local damage [12]. Research
into BBB disruption in TBM is sparse, but evidence indicates that MMP levels are increased in
TBM [19,43,44,46,47], suggesting that they play a key role in BBB-breakdown, thereby contributing to the
pathogenesis of TBM. The level and presence of specific MMPs and their inhibitors in the cerebrospinal
fluid (CSF) and blood of patients may therefore be markers of BBB compromise. However, human
studies have not shown association between MMP concentrations and the CSF-serum albumin index,
an accepted index of BBB breakdown [47,52,53].
4.2. MMPs in Neuro-Inflammation
As summarized in Figure 2, MMPs contribute to ECM destruction in CNSTB. The two MMPs that
have been the focus of human TBM research to date include MMP-2 and MMP-9 and their respective
inhibitors, TIMP-2 and TIMP-1. MMP-2, also known as gelatinase-A, is a constitutively-expressed
molecule that is present in large quantities in the normal brain and is found in astrocytes and CSF [9].
MMP-9, or gelatinase-B, is normally absent or present at low levels in the brain. It is found to be
up-regulated during neuroinflammation [6], specifically in conditions such as viral and bacterial
meningitis [88,89]. Together, these gelatinases digest tenascins, proteoglycans, fibronectin, type IV
collagen, and laminin found in basement membranes of the BBB and ECM of the CNS, and thus are
likely to contribute to the degradation of the BBB and tissue destruction [6,19,46]. This BBB degradation
drives cerebral vasogenic oedema and facilitates further influx of blood-derived inflammatory cells
into the CNS. The resultant chronic fibrosis and adhesions (due to exudate formation) contribute to the
complications and neurological sequelae of TBM discussed below. In contrast to MMPs, TIMPs are
widely expressed in many mammalian tissues. In the CNS, TIMP-1 expression is restricted to regions
of persistent neuronal plasticity, such as the hippocampus, cerebellum, and olfactory bulb [11].
Cell culture models suggest that astrocyte and microglial secretion of MMPs does not occur
with direct Mtb infection of these cells but rather in response to Mtb-infected monocytes as part of a
leukocyte-astrocyte and leukocyte-microglia interaction, leading to the release of MMP-9, -1, and -3,
respectively [12,20,21]. This network-dependent MMP expression is driven by pro-inflammatory
mediators including TNF-α and IL-1β and IL-1β’s synergistic interaction with IFN-γ in the case of
MMP-9. The transcription of MMP-9 is regulated by MAPK and NF-κβ [12], while MMP-1 and -3
transcriptional regulation occurs through p38 MAPK pathway, NF-κβ and AP-1 [20,90]. In contrast to
other MMPs, MMP-2 secretion from microglia is inhibited by cytokines, such as TNF-α, through p38,
caspase 8, and NF-κβ signaling [91]. Additionally, TIMP expression is not influenced by these cellular
networks, suggesting a possible shift to matrix degradation in response to TB. MMP-3 may also be
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released by apoptotic neurons, resulting in the activation of microglia [12] and contributing to BBB
breakdown by digesting the basal lamina and tight-junction proteins, specifically claudin-5, occludin,
and laminin-α1 [92]. The breakdown of the BBB facilitates an influx of neutrophils that exacerbate
BBB damage by secreting MMP-9 (also activated by MMP-3) through a monocyte-neutrophil network
regulated by MAPK and Akt-PI3K [21,92]. MMP-9 is also reported to specifically target myelin basic
protein in the white matter, which can negatively affect neuronal myelination [93]. The source of MMP
secretion in the CNS is therefore likely a combination of infiltrating monocytes and neutrophils as well
as resident astrocytes and microglia.
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Figure 2. MMPs contribute to extracellular matrix (ECM) destruction in CNS TB. Mtb bacilli cross the
protective blood brain barrier (BBB) through various mechanisms, including in infected monocytes.
In the presence of these infected monocytes and driven by TNF-α and interleukin (IL)-1β, brain
microglia and astrocytes respond as part of a leukocyte-microglia and leukocyte-astrocyte interaction
by secreting MMP-1, -2, and -9, and MMP-1 and -3, respectively. These MMPs contribute to the
breakdown of ECM proteins of the brain parenchyma, including fibronectin, laminin-α1, collagen type
IV, and proteoglycans, and are pro-apoptotic to neurons (indicated in red text as “cell death”) with
the resultant tissue destruction adding to the cerebral inflammatory response. MMP-9 is also known
to attack myelin basic protein (MBP), an integral component of the myelin sheath insulating neurons.
Further, MMPs degrade claudin-5 and occludin, thereby compromising the tight BBB and contributing
to the influx of proteins and water resulting in vasogenic edema, as well as further blood-derived
inflammatory cells, including neutrophils. Neutrophils secrete MMP-9 in the parenchyma as well as
in TB granulomas (tuberculomas), in which Mtb-infected microglia have also been found to secrete
MMP-1 and -3. Contrary to the other MMPs, MMP-2 expression is suppressed through cytokines like
TNF-α. Up-arrow indicates increased concentrations, down-arrow indicates decreased concentrations.
4.3. MMPs in TBM
The role of MMPs in TBM is summarized in Table 1, section B. Elevated MMP-9 concentrations
have been found in the CSF of TBM patients with the degree of elevation correlated with the severity
of disease [50], neurological compro ise [19,44], and brain tissue injury [43,44]. Matsuura et al.
demonstrated that concentrations of MMP-2 and -9 as well as TIMP-1 (but not TIMP-2) in the CSF
were increased in patients with subacute (involving tubercle bacilli or mycotic organisms) meningitis
co pared with controls, and MMP-9 levels associated with CNS complications (such as disturbances
of consciousness and psychiatric symptoms) [43]. Similarly, a study by Lee et al. demonstrated that
increased MMP-2 and -9 levels in the CSF persisted during the late course of TBM and were associated
Int. J. Mol. Sci. 2019, 20, 1350 23 of 35
with the development of complications [46]. Price et al. demonstrated that the imbalance of MMP-9
versus TIMP-1 in the CSF of TBM patients correlates with morbidity and mortality [94]. Although
Green et al. found that adjunctive dexamethasone was associated with a significant decrease in CSF
MMP-9 concentrations, they did not find an association between a decline in MMP-9 concentrations
and improved outcome [47].
However, the association of elevated MMP-2 and -9 concentrations with poor outcome is not
consistent across TBM studies, and numerous studies have demonstrated no association between
MMP concentrations and outcome [45,48,52,53]. In fact, Mailankody et al. demonstrated an association
between elevated MMPs and a favorable outcome, and the authors postulated that the MMP
contribution to a leaky BBB may be favorable to anti-TB drug penetration and could therefore offer an
advantage to recovery [52]. In a pediatric TBM study, the beneficial effect of MMPs was corroborated by
a 2.2 times greater likelihood of a better outcome associated with an increase in MMP-9 concentrations
in the early weeks after hospitalization [53]. It is known that MMP-9 can mediate both protective and
pathological immunity at different concentrations and in different age groups [94], and this raises
questions about the role of MMP-9 in pathology—and potentially recovery—at different time points
during the disease course. Similar challenges have been encountered in therapeutically targeting
MMPs in oncology, reflecting the complexity of protease networks in human disease [95].
TBM is often associated with localized TB granulomas (tuberculomas) [96], which demonstrate
elevated MMP-1, -3, and -9 expression [19–21]. In brain biopsies from patients with CNS TB, MMP-1
secretion was highest in the granuloma, and elevated concentrations of MMP-1 and -3 were associated
with microglia in the peri-granuloma region and surrounding brain parenchyma and p38 positive
microglia infiltrating necrotizing TB granulomas [20,91]. Using similar samples, Ong et al. also
demonstrated MMP-9 secreting neutrophil presence in these CNS TB granulomas [21].
4.4. MMPs in TBM-IRIS
TBM-IRIS is a frequent, severe complication of ART in HIV-associated TBM patients. A prospective
study of HIV-infected ART-naive patients with TBM showed that 47% (16/34) of TBM patients
developed TBM-IRIS [97]. Patients who went on to develop TBM-IRIS had higher CSF neutrophil
counts compared with non-TBM-IRIS patients and were more likely to have Mtb cultured from CSF at
TBM presentation. The relative risk of developing TBM-IRIS was 9.3 (CI: 1.4–62.2) if the CSF was Mtb
culture positive, indicating that the condition is driven by Mtb antigen load. This study also showed
that a combination of IFN-γ and TNF-α concentrations measured in the CSF may predict TBM-IRIS,
potentially paving the way for CSF immunodiagnostics. Subsequently, the concentration of 40 immune
mediators in CSF (33 paired with blood) from HIV-infected patients with TBM was determined at
TBM diagnosis, at initiation of antiretroviral therapy (ART, day 14), 14 days after ART initiation, at
presentation of TBM-IRIS, and 14 days thereafter [49]. Among others, MMP-1, -2, -3, -7, -9, -10, -12,
and -13, and TIMP-1 and -2 were analyzed using Luminex multiplex assays in CSF and plasma of
patients who developed TBM-IRIS (n = 16) compared to those who did not (TBM-non-IRIS; n = 18).
Patients who developed TBM-IRIS had higher concentrations of MMP-1, -3, -7, and -10 in their
blood, while MMP-9 and TIMP-1 were higher in CSF relative to blood at the time of TBM diagnosis
and at the time of starting ART, as well as at the time of developing TBM-IRIS symptoms, when their
concentrations increased further. However, CSF MMP-9 concentrations did not decrease following
anti-TB and corticosteroid therapy and continued to rise following ART initiation, suggesting that
more potent and specific therapy may be needed for the management of TBM-IRIS [98]. Overall, both
at TBM diagnosis and at two weeks after ART initiation, TBM-IRIS was associated with severe
compartmentalized inflammation in the CSF, elevated concentrations of cytokines, chemokines,
neutrophil-associated mediators, and MMPs compared with TBM-non-IRIS, and driven by a high
baseline Mtb antigen load [49]. A longitudinal whole-blood microarray analysis of HIV-infected
patients with TBM confirmed the more abundant neutrophil-associated transcripts in patients who
went on to develop TBM-IRIS from before symptom development through to TBM-IRIS symptom
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onset. This study also demonstrated a significantly higher abundance of transcripts associated
with canonical and noncanonical inflammasomes in patients with TBM-IRIS compared to non-IRIS
controls [51]. These findings, reflected at the protein and molecular level, suggest a dominant role for
the innate immune system in the pathogenesis of TBM-IRIS, offer mechanistic insights into the disease,
and inform potential future directions for host-directed therapy. It is notable that when patients with
HIV-associated TBM were compared to those with HIV-associated cryptococcal meningitis, MMP-1
and -3 were more elevated in the former and MMP-10 in the latter, suggesting that MMP profiles may
differ across meningitides of varying etiologies [99].
4.5. Adults and Children
Before the era of HIV, the most important risk factor for TBM was age, with young children
(aged 0–4) bearing the brunt of the disease [100,101]. This is possibly due to children having an
immature immune system less capable of halting TB dissemination after primary infection [100,101].
However, apart from their role in neuro-inflammation, MMPs also play a unique role in normal
brain development. Several animal studies have shown that MMPs, specifically MMP-2, -3, and -9,
have a crucial role in the developing brain. For example, mice lacking MMP-9 have maladapted
neuronal circuitry with simplified dendritic morphology, abnormal synaptic structure and function,
and enhanced excitability [102]. MMP-3 and -2 are expressed in the cortical neurons of young mice
and are required for appropriate axonal outgrowth and orientation [16,103]. Van Hove et al. also
found that MMP-3 deficient mice developed deficits in balance and motor performance related to
abnormal cerebellar development [104]. Despite the high prevalence of TBM in children, MMPs
during pediatric TBM infection have not been well studied. In our recent pediatric TBM study [53],
the positive association between increasing MMP-9 concentrations and good outcome may suggest
a role in recovery and ongoing neurodevelopment, possibly including angio- and myelino-genesis,
the growth of axons and synaptic plasticity. Similarly, the positive correlation found between MMP-2
and TIMP-2 may also suggest a physiological role in remodeling ECM in the developing CNS [53].
However, further studies with appropriate comparison with adults are required.
5. Treatment
5.1. MMP Inhibition in pTB
Multiple host-directed therapies centered on modulating protease activity have been evaluated in
animal models (Table 2) as adjuncts to antibacterial treatment in TB with the prospect of beneficial
immune modulation leading to enhanced bacterial clearance and the reduction of tissue damage
and inflammation, thereby potentially shortening treatment duration [105]. This is challenging given
the complexity of the host immune response. For example, multiple drugs that target upstream
inflammatory pathways can have an effect on MMP expression by indirectly inhibiting their activity
(e.g., prednisone, doxycycline, vitamin D, rapamycin) [106]. Similarly, non-specific immunomodulation
of the host response with corticosteroids has been evaluated in pTB, with most studies showing no
added benefit compared to standard treatment alone [107]. Conversely, in cases of extra-pulmonary TB,
such as TBM and TB pericarditis, adjuvant use of corticosteroids has been shown to reduce mortality
and morbidity, leading to their common use in current clinical practice [108]. Doxycycline, a tetracycline
antibiotic, has been shown to non-specifically inhibit multiple MMPs independently of its antimicrobial
activity [109]. However, doxycycline also has immunomodulatory effects on other host inflammatory
pathways, confounding its potential MMP-specific effects [110]. Walker et al. reported that doxycycline
modulated MMP expression in Mtb-infected cells and reduced mycobacterial growth in vivo [28].
However, additional studies are necessary to evaluate the potential of doxycycline as MMP-inhibitor
therapy in TB. Indirect inhibition of MMPs has also been reported with a phosphodiesterase-4 inhibitor
(CC-3052) in a rabbit model of TB [111]. CC-3052 plus isoniazid significantly reduced the extent of
immune pathology and the expression of MMPs compared with antibiotics alone.
Int. J. Mol. Sci. 2019, 20, 1350 25 of 35
A more specific approach to evaluating MMP-inhibition in pTB has also been attempted with
multiple specific MMP inhibitors (e.g., batimastat, cipemastat, marimastat) using different animal
models of pTB. However, these studies have generated conflicting data, and the differences in treatment
regimens, bacterial burden, host immune response, and variables measured make direct comparisons
difficult (Table 2).
Initial experiments focused on monotherapy with MMP inhibitors in mouse models of pTB.
Batimastat (BB-94), a potent broad-spectrum inhibitor, showed promising results in cancer models
and was one of the first MMP inhibitors to enter clinical trials [112]. However, its poor solubility
and side effects associated with intraperitoneal dosing led to its discontinuation. In pTB models,
Hernandez-Pando et al. used Mtb-infected Balb/c mice to show a trend towards increased mortality if
the treatment with batimastat was started immediately after infection with Mtb [113]. However, the
increased mortality and histological differences were not evident between treated and control groups
if batimastat was initiated a month after infection. Overall, there was a shift towards a type-2 cytokine
profile and delayed granuloma formation in treated mice compared to controls. Subsequent studies by
Izzo et al. using batimastat in C57BL/6 mice infected with Mtb showed reduced bacterial burden and
smaller granulomas with more collagen deposition at earlier stages (day 40), but no differences were
seen at day 60 post-infection [114]. However, a follow up study by the same group did not observe
a reduced bacterial burden in the same mouse model when batimastat was initiated right after Mtb
infection [115].
Recently, Urbanowski et al. used cipemastat, an orally available MMP inhibitor, in a rabbit model
of cavitary pTB with repeated aerosol exposures to Mtb [116]. Compared to controls, monotherapy
with cipemastat during week five to ten post-infection did not reduce the rates of cavitation evaluated
by CT, mitigate disease severity, or visibly affect the collagen structure of the cavitary wall (examined
post-mortem). Conversely, the cipemastat-treated group had a trend toward worse cavitary disease.
Ordonez et al. used cipemastat monotherapy in the C3HeB/FeJ mouse model that develops cavitary
lesions after aerosol infection with Mtb [117]. Similar to rabbits, cipemastat-treated mice had worse
cavitation and more disease severity compared to controls.
While monotherapy with MMP inhibitors suggested worse outcomes, the use of multiple
MMP inhibitors (marimastat, batimastat, or SB-3CT) in combination with anti-TB therapy have had
synergistic effects in reducing the Mtb burden in a pTB mouse model [118]. While no effect on bacterial
burden was observed with marimastat treatment alone, its combination with isoniazid significantly
reduced lung colony forming units compared to isoniazid alone. Marimastat also reduced vascular
leakage surrounding TB granulomas and increased the concentration of isoniazid in Mtb-infected
lungs compared to controls. Similarly, targeting MMP-9 with a specific antibody in addition to anti-TB
therapy (rifampin, pyrazinamide, and isoniazid) reduced pulmonary bacterial burden and significantly
lowered relapse rates in a cavitary mouse model of pTB [117]. Therefore, MMP inhibition in conjunction
with antibiotic therapy may be beneficial, whilst MMP inhibition monotherapy seems to be harmful,
further demonstrating the complexity of events in vivo and the importance of performing translational
preclinical studies that most closely reflect the intended therapeutic use in patients.
Int. J. Mol. Sci. 2019, 20, 1350 26 of 35
Table 2. Evaluation of MMP inhibitors in pulmonary TB animal models.
MMP Inhibitor Animal Model
Treatment
Started *
Combination
Therapy
Results in Treated Group Compared to Controls
Reference
Lung CFU LungPathology Mortality
Other Findings in Treated
Group
Batimastat
(BB-94)
Mouse (Balb/c)
Day 1 No NR + + Lower TNF-α, IL-2 and IL-1α.Higher IL-4 [113]
Day 30 No NR = =
No difference in TNF-α, IL-2 and
IL-4. Higher IL-1α in pneumonic
areas.
[113]
Mouse
(C57BL/6)
Day 18 No − −/= a NR
Decreased leukocytes. No
differences in IFN-γ, IL-4, IL-12,
TNF-α and IL-10. Less CFU in
blood.
[114]
Day 1 No = NR NR Less CFU in spleen and blood byday 14. [115]
Day 7 Isoniazid − NR NR [118]
Cipemastat
(Ro 32-3555,
Trocade)
Mouse
(C3HeB/FeJ) Day 1 No = + + Higher rate of cavitation [119]
Rabbit (New
Zealand white) Day 35 No NR + NR
Higher rate of cavitation. No
differences in disease severity by
gross pathology or histology
[116]
Marimastat
(BB-2516)
Mouse
(C57BL/6)
Day 7 No = = NR [118]
Day 7 Isoniazid − − NR Improved stability of bloodvessels surrounding TB lesions [118]
Prinomastat Mouse(C57BL/6) Day 7 Isoniazid = NR NR [118]
SB-3CT Mouse(C57BL/6) Day 7 Isoniazid − NR NR [118]
MMP-9 inhibitor I Mouse(C57BL/6) Day 7 Isoniazid − NR NR [118]
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Table 2. Cont.
MMP Inhibitor Animal Model
Treatment
Started *
Combination
Therapy
Results in Treated Group Compared to Controls
Reference
Lung CFU LungPathology Mortality
Other Findings in Treated
Group
Anti MMP-9
antibody
Mouse
(C3HeB/FeJ) Day 42
Rifampin,
isoniazid and
pyrazinamide
− − NR Less relapse rates after 12 weeksof treatment [117]
CC-3052
(PDE-4 inhibitor) b
Rabbit (New
Zealand white)
Day 28 No = + NR Worse disease compared tountreated controls [111]
Day 28 Isoniazid − − NR
Less inflammation and fibrosis
compared to isoniazid
monotherapy controls
[111]
Doxycycline Guinea pig Day 14 No − − NR No MMP-specific effect ofdoxycycline was identified [28]
* Days post-infection with M. tuberculosis, (−) equals less disease, (+) equals worse disease, (=) no change. NR = not reported, a Smaller pulmonary granulomas with more collagen
deposition by day 40. No difference in pathology compared to controls by day 60. b Phosphodiesterase-4 inhibitor. Tumor necrosis factor (TNF), interleukin (IL), colony forming
units (CFU).
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5.2. MMP-Inhibition in CNS TB
Given the important role MMPs have in the degradation of the BBB and tissue destruction in CNS
TB, MMPs are a possible target for adjunctive treatment. In vitro CNS TB studies have demonstrated
that dexamethasone leads to a decrease in MMP-1 and -3 mRNA expression and secretion without
impacting TIMP expression. This has been suggested as a mechanism by which steroids improve
short-term mortality from TBM [20]. NF-κβ inhibition and anti-TNF-α have been shown to decrease
neutrophil expression of MMP-9, which is postulated as one mechanism by which to decrease CNS
destruction [21]. Given the pro-inflammatory network involvement in MMP-9 expression, it has been
suggested that targeting this network may offer opportunities for MMP regulation without directly
interfering with the role of MMPs in the host defense against Mtb [12]. In TBM-IRIS, protein and
transcriptome studies have highlighted the role of a neutrophil driven and inflammasome-associated
inflammatory response in disease pathogenesis [49,51]. ECM destruction due to neutrophil secretion of
MMP-9 is suggested to contribute to brain tissue damage, and pyroptosis driven by caspase-1 secretion
may cause further injury. Agents specifically targeting the inflammasome could therefore offer another
potential avenue for host-directed therapy.
Although MMP secretion may be affected by several medications, there has also been interest in
developing drugs to specifically target MMPs. Paul et al. evaluated the effect of the MMP inhibitor
Batimastat (BB-94) on BBB breakdown (as measured by Evans Blue leakage) and increased intracranial
pressure (ICP—measured via catheter) using a rat model of meningococcal meningitis. The disruption
of the BBB (and subsequent pathological changes) was ameliorated in animals treated with BB-94 in a
dose-dependent manner [120]. Majeed et al. used an MMP-9 specific inhibitor SB-3CT [50,121], which
appeared more effective than dexamethasone in that it suppressed MMP-9 and enhanced the effect of
anti-TB drugs on clearing TB bacilli [121].
6. Conclusions
Evidence suggests that MMPs are an important component of the inflammatory response to
Mtb infection and the consequent breakdown of the ECM in both the lungs and the brain. Their
potential role in brain development suggests that MMPs may be relevant in both normal physiology
and pathophysiology. However, they form part of an elaborate network of inflammation and injury
and constitute one element of a complex inflammatory process in TB. A better understanding of what
contributes to MMP-mediated tissue damage and the role of MMPs in the broader disease context is
needed to develop targeted treatment strategies that may limit pathology or prevent cavitation and
transmission without the risk of unexpected effects.
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